Poxel SA

7PO

Company Profile

  • Business description

    Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

  • Contact

    259/261 Avenue Jean Jaures
    Immeuble le Sunway
    Lyon69007
    FRA

    T: +33 437372010

    https://www.poxel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

Cheap retail REIT with an attractive yield

Lower consumer spending unlikely to buckle this retail REIT.
stocks

Expanding store network for ASX listed retailer

Sales growth but lack of margin expansion due to competition.
stocks

3 cheap fully franked stocks

Discounted Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,125.2065.700.73%
CAC 408,384.0133.140.40%
DAX 4024,894.01258.711.05%
Dow JONES (US)51,671.03468.770.92%
FTSE 10010,430.6241.10-0.39%
HKSE24,550.38292.29-1.18%
NASDAQ26,683.94795.103.07%
Nikkei 22569,592.99275.490.40%
NZX 50 Index13,426.1365.540.49%
S&P 5007,554.29122.831.65%
S&P/ASX 2008,911.1070.700.80%
SSE Composite Index4,099.853.380.08%

Market Movers